These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 25139487)

  • 1. Systemic exposure of topical erythromycin in comparison to oral administration and the effect on cytochrome P450 3A4 activity.
    Carls A; Jedamzik J; Witt L; Hohmann N; Burhenne J; Mikus G
    Br J Clin Pharmacol; 2014 Dec; 78(6):1433-40. PubMed ID: 25139487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the treatment period with erythromycin on cytochrome P450 3A activity in humans.
    Okudaira T; Kotegawa T; Imai H; Tsutsumi K; Nakano S; Ohashi K
    J Clin Pharmacol; 2007 Jul; 47(7):871-6. PubMed ID: 17585116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-Dependent Bioavailability and CYP3A Inhibition Contribute to Non-Linear Pharmacokinetics of Voriconazole.
    Hohmann N; Kocheise F; Carls A; Burhenne J; Weiss J; Haefeli WE; Mikus G
    Clin Pharmacokinet; 2016 Dec; 55(12):1535-1545. PubMed ID: 27236320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humans.
    Hohmann N; Kocheise F; Carls A; Burhenne J; Haefeli WE; Mikus G
    Br J Clin Pharmacol; 2015 Feb; 79(2):278-85. PubMed ID: 25588320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes.
    Mathijssen RH; de Jong FA; van Schaik RH; Lepper ER; Friberg LE; Rietveld T; de Bruijn P; Graveland WJ; Figg WD; Verweij J; Sparreboom A
    J Natl Cancer Inst; 2004 Nov; 96(21):1585-92. PubMed ID: 15523087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation.
    Budha NR; Ji T; Musib L; Eppler S; Dresser M; Chen Y; Jin JY
    Clin Pharmacokinet; 2016 Nov; 55(11):1435-1445. PubMed ID: 27225997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of CYP3A inhibition on the metabolism of cilostazol.
    Suri A; Forbes WP; Bramer SL
    Clin Pharmacokinet; 1999; 37 Suppl 2():61-8. PubMed ID: 10702888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of the Selective Orexin-1 Receptor Antagonist ACT-539313 on the Pharmacokinetics of the CYP3A Probe Drug Midazolam in Healthy Male Subjects.
    Berger B; Kaufmann P; Koch A; Dingemanse J
    J Clin Pharmacol; 2020 Jul; 60(7):931-941. PubMed ID: 32035014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Erythromycin as a Tool to Assess CYP3A Contribution of Low Clearance Compounds in a Long-Term Hepatocyte Culture.
    Chan TS; Scaringella YS; Raymond K; Taub ME
    Drug Metab Dispos; 2020 Aug; 48(8):690-697. PubMed ID: 32503882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of inter-racial variability in CYP3A4 activity and inducibility among healthy adult males of Caucasian and South Asian ancestries.
    van Dyk M; Marshall JC; Sorich MJ; Wood LS; Rowland A
    Eur J Clin Pharmacol; 2018 Jul; 74(7):913-920. PubMed ID: 29572563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoinhibitory properties of the parent but not of the N-oxide metabolite contribute to infusion rate-dependent voriconazole pharmacokinetics.
    Hohmann N; Kreuter R; Blank A; Weiss J; Burhenne J; Haefeli WE; Mikus G
    Br J Clin Pharmacol; 2017 Sep; 83(9):1954-1965. PubMed ID: 28370390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin.
    Elens L; Nieuweboer AJ; Clarke SJ; Charles KA; de Graan AJ; Haufroid V; van Gelder T; Mathijssen RH; van Schaik RH
    Pharmacogenet Genomics; 2013 Mar; 23(3):148-55. PubMed ID: 23324807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
    Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
    Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice.
    Veronese ML; Gillen LP; Burke JP; Dorval EP; Hauck WW; Pequignot E; Waldman SA; Greenberg HE
    J Clin Pharmacol; 2003 Aug; 43(8):831-9. PubMed ID: 12953340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity.
    Kurnik D; Wood AJ; Wilkinson GR
    Clin Pharmacol Ther; 2006 Sep; 80(3):228-34. PubMed ID: 16952489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effect of CYP3A Induction and Inhibition on the Pharmacokinetics of Laquinimod, a Novel Neuroimmunomodulator.
    Elgart A; Greenblatt DJ; Loupe PS; Zur AA; Weiss S; Mimrod D; Spiegelstein O
    Clin Pharmacol Drug Dev; 2020 Nov; 9(8):1015-1024. PubMed ID: 32237115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Cytochrome P450 3A4 Inhibitors-Ketoconazole and Erythromycin-on Bitopertin Pharmacokinetics and Comparison with Physiologically Based Modelling Predictions.
    Boetsch C; Parrott N; Fowler S; Poirier A; Hainzl D; Banken L; Martin-Facklam M; Hofmann C
    Clin Pharmacokinet; 2016 Feb; 55(2):237-47. PubMed ID: 26341813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of fluvoxamine and erythromycin on the pharmacokinetics of oral lidocaine.
    Isohanni MH; Neuvonen PJ; Olkkola KT
    Basic Clin Pharmacol Toxicol; 2006 Aug; 99(2):168-72. PubMed ID: 16918719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug Interactions for Low-Dose Inhaled Nemiralisib: A Case Study Integrating Modeling, In Vitro, and Clinical Investigations.
    Patel A; Wilson R; Harrell AW; Taskar KS; Taylor M; Tracey H; Riddell K; Georgiou A; Cahn AP; Marotti M; Hessel EM
    Drug Metab Dispos; 2020 Apr; 48(4):307-316. PubMed ID: 32009006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. I: evaluation of cynomolgus monkeys as surrogates for humans.
    Kanazu T; Yamaguchi Y; Okamura N; Baba T; Koike M
    Xenobiotica; 2004 May; 34(5):391-402. PubMed ID: 15370956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.